Retatrutide and gray hair: what we know

A question keeps resurfacing on peptide forums: does retatrutide turn your hair gray? Eli Lilly's investigational triple agonist retatrutide has generated a small number of anecdotal reports, including a thread on r/peptides where a user describes a few extra white hairs in the beard and at the temples a couple of months after starting a low dose^[5]. Here is the honest position. There is no established causal link between retatrutide and hair greying, the published Phase 3 adverse-event tables do not list it^[4], and the mechanisms people reach for are mostly borrowed from the hair-loss literature rather than proven for pigment.

What the trial and label data report

Retatrutide's documented side effects are dominated by the gut. The TRIUMPH-1 Phase 3 topline in 2,339 adults reported nausea in up to 42.4% of participants, along with diarrhoea, vomiting, constipation, and a dose-dependent dysesthesia (a tingling or altered skin sensation) signal. Hair changes of any kind were not among the reported events^[4]. Across the wider GLP-1 class the hair side effect that has reached drug labelling is loss, not colour. The tirzepatide products behind Mounjaro and Zepbound list hair loss, while greying appears nowhere. That distinction matters. Shedding is documented. Depigmentation is not.

The weight-loss thread: shedding, not colour

The one hair mechanism with real support connects these drugs to the follicle through weight loss rather than pigment. A 2026 review in Dermatology and Therapy (Piraccini and colleagues) attributes GLP-1 associated shedding to telogen effluvium, the synchronized shift of many follicles into a resting phase after a rapid drop in body weight^[1]. Telogen effluvium changes how much hair you shed and then regrow. It does not strip colour from the hairs that stay put. Where someone already has scattered greys coming in, a heavy shed followed by regrowth can make those white hairs more obvious, but that is a matter of timing and contrast, not the drug bleaching a follicle. The same shedding signal is reported for semaglutide and tirzepatide, and we cover it in full in our companion piece on GLP-1 drugs and hair loss.

The nutrition thread: copper, B12 and greying

The more interesting thread runs through nutrition. Premature greying is mostly written into your genes. Twin studies attribute as much as 90% of the variation to genetics, with oxidative stress and diet making up the modifiable rest. A 2025 review in the International Journal of Dermatology (Desai and colleagues) catalogues the nutritional associations, including lower serum copper, vitamin B12, iron, and zinc in people who grey early^[2]. Copper is the one worth pausing on, because tyrosinase, the enzyme that assembles melanin, cannot work without it.

Frank copper deficiency can cause defective keratinization and pigmentation of the hair, and its classic drivers are upper gastrointestinal surgery and malabsorption^[3]. Retatrutide is not surgery, but it does produce large and fast weight loss (28.3% at the top dose in TRIUMPH-1) largely by cutting how much people eat^[4], and sharply restricted eating can open micronutrient gaps. That is a plausible pathway, not a demonstrated one. Nobody has measured copper, B12, or pigment outcomes in retatrutide users.

The bariatric-surgery literature is the closest real-world comparison. Copper and B12 deficiencies are well documented after gastric bypass, sometimes years later, precisely because the surgery limits how much of these micronutrients the gut can absorb^[3]. GLP-1 and triple-agonist drugs reach similar weight-loss numbers without cutting the bowel, so the absorption route stays intact, but the reduced-intake side of the equation still applies. That is a reason to eat and supplement deliberately during fast weight loss, not a reason to expect grey hair.

About the GHK-Cu idea

The forum poster was also using GHK-Cu, a copper-carrier peptide, and asked whether raising the dose would fix the greying^[5]. We would not read it that way. There are no controlled human trials showing GHK-Cu restores hair colour, and the copper-peptide hair claims sit in cosmetic marketing rather than clinical evidence. Adding more of one unapproved peptide to counter a suspected effect of another is guesswork stacked on guesswork. If a genuine copper deficiency is the concern, that is a diagnosis and a correction a clinician makes from bloodwork, not something to titrate by feel.

What we still do not know

Almost everything specific to this question is open. We do not know whether retatrutide affects pigment at all, because no study has looked. We do not know whether its weight loss creates copper or B12 gaps large enough to touch hair colour. And we cannot separate the greys people notice on the drug from the ordinary background rate, which becomes a lot more visible once you start inspecting your beard in the mirror. Genetics still explains most greying, at any age. If new greys show up while you are on a GLP-1 drug, the useful step is a conversation with your prescriber and, if warranted, bloodwork. You can read our full retatrutide overview and its safety section for the wider adverse-event picture, and the regulatory status for why an unapproved compound is hard to study this way in the first place.

Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.